指南与共识儿科与产科急症消化、代谢与肾脏急症

免疫功能低下患者的COVID-19疫苗接种:证据与建议评述

COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations.
指南 / 共识 · Am J Health Syst Pharm · 2022-01-01
一句话结论美国CDC、英国免疫学会等机构推荐免疫功能低下患者接种COVID-19疫苗,疫苗获益预期大于理论风险。

本文评述了COVID-19疫苗在免疫功能低下人群中的证据与推荐,聚焦HIV感染、实体器官移植、类风湿关节炎和炎症性肠病四类患者。III期试验主要排除免疫功能低下者,仅HIV感染者被纳入;近期回顾性试验提供了疫苗安全性的数据,Moderna III期试验中期分析显示HIV感染者中的有效性数据令人鼓舞。美国CDC、英国免疫学会等多个政府和专业学会推荐免疫功能低下人群接种COVID-19疫苗。作者认为,尽管仍需更多数据明确免疫抑制疾病和药物对疫苗效果的影响,但当前推荐接种,并应通过教育减少疫苗犹豫。

要点

  • 美国CDC、英国免疫学会等多个政府和专业学会推荐免疫功能低下患者接种COVID-19疫苗。
  • III期COVID-19疫苗试验主要排除免疫功能低下者,仅HIV感染者被纳入。
  • 近期回顾性试验提供了免疫功能低下患者接种COVID-19疫苗安全性的令人安心的数据。
  • Moderna III期试验中期分析显示HIV感染者中的有效性数据令人鼓舞。
  • 作者认为疫苗获益预期大于理论风险,推荐当前为免疫功能低下患者接种,并通过教育减少疫苗犹豫。

适用人群与场景

  • 纳入讨论的免疫功能低下人群:HIV感染、实体器官移植、类风湿关节炎、炎症性肠病患者。

研究设计与关键结果

  • 本文为评述文章,聚焦HIV感染、实体器官移植、类风湿关节炎和炎症性肠病四类免疫功能低下患者。
  • III期COVID-19疫苗试验主要排除免疫功能低下者,仅HIV感染者被纳入。
  • 近期回顾性试验提供了COVID-19疫苗在免疫功能低下患者中安全性的令人安心的数据。
  • Moderna III期试验中期分析显示HIV感染者的有效性数据令人鼓舞。
  • 美国CDC、英国免疫学会及多个政府和专业学会推荐免疫功能低下人群接种COVID-19疫苗。

证据类型、等级与局限

  • 证据类型:评述文章,汇总III期试验、回顾性试验和学会推荐。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管仍需更多数据明确免疫抑制疾病和药物对疫苗效果的影响,疫苗获益预期大于理论风险。
  • 作者建议当前为免疫功能低下患者接种COVID-19疫苗,并通过教育和 reassurance 减少该人群的疫苗犹豫。

指南或共识出处

  • 美国CDC、英国免疫学会及其他政府和专业学会的推荐(原文未列具体指南名称和年份)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: While COVID-19 vaccine emergency use authorization (EUA) deemed the vaccines to be effective and safe for public use, the phase 3 trials leading to EUA predominantly excluded patients with immunocompromising conditions. Immunocompromised patients make up a significant proportion of the population, and in light of recent mass vaccination efforts, we aim to review current evidence and recommendations of COVID-19 vaccines in 4 patient populations with immunocompromising disorders or conditions: human immunodeficiency virus (HIV) infection, solid organ transplantation, rheumatoid arthritis, and inflammatory bowel disease.

SUMMARY: Given the evolving data on the safety and efficacy of the approved COVID-19 vaccines in the immunocompromised population, it is vital that pharmacists and other immunizing providers understand the current data and recommendations and provide the public with accurate information. To date, the only immunocompromised subgroup included in phase 3 COVID-19 vaccine trials have been those with HIV infection. However, recent retrospective trials have provided reassuring data on the safety of the COVID-19 vaccine in immunocompromised patients, and the interim analysis of the Moderna phase 3 trial produced promising data on efficacy in HIV-infected patients. Presently, the US Centers for Disease Control and Prevention, British Society for Immunology, and various other governmental and professional societies and organizations endorse COVID-19 vaccination in the immunocompromised population.

CONCLUSION: While additional data is needed to determine the effects of immunocompromising medical conditions and immunosuppressing medications on the efficacy of the vaccine, the benefits of vaccination is anticipated to outweigh theoretical risks. Thus, COVID-19 vaccination is recommended for immunocompromised patients at this time, and providers should make efforts to decrease vaccine hesitancy in this population through education and reassurance.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

参考来源

  1. Duly K, Farraye FA, Bhat S, et al. COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations. Am J Health Syst Pharm. 2022. PMID: 34455440. doi:10.1093/ajhp/zxab344

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。